Citations

Clear

1790 citation(s) found for "Yu, Stephanie".

Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome
Bierle, Dennis M. , Aakre, Christopher A. , Grach, Stephanie L. , Salonen, Bradley R. , Croghan, Ivana T. , Ganesh, Ravindra , Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L

Mayo Clinic

Journal of Primary Care & Community Health | July 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211030826 | PMID 34231404 Get It

Objective To develop and implement criteria for description of post COVID syndrome based on analysis of patients presenting for evaluation at Mayo Clinic Rochester between November 2019 and August 2020. Methods A total of 465 patients with a history of testing positive for COVID-19 were identified and their medical records reviewed. After a thorough review, utilizing the DELPHI methods by an expert panel, 42 (9%) cases were identified with persistent central sensitization (CS) symptoms persisting after the resolution of acute COVID-19, herein referred to as Post COVID syndrome (PoCoS). In this report we describe the baseline characteristics of these PoCoS patients. Results Among these 42 PoCoS patients, the mean age was 46.2 years (median age was 46.5 years). Pain (90%), fatigue (74%), dyspnea (43%), and orthostatic intolerance (38%) were the most common symptoms. The characteristics of an initial 14 patients were utilized for the development of clinical criteria via a modified Delphi Method by a panel of experts in central sensitization disorders. These criteria were subsequently applied in the identification of 28 additional cases of suspected PoCoS. A 2-reviewer system was used to analyze agreement with using the criteria, with all 28 cases determined to be either probable or possible cases by the reviewers. Inter-reviewer agreement using these proposed defining criteria was high with a Cohen’s alpha of .88. Conclusions Here we present what we believe to be the first definitional criteria for Post COVID syndrome. These may be useful in clinical phenotyping of these patients for targeted treatment and future research.
PROMIS Scales for Assessment of Persistent Post-COVID Symptoms: A Cross Sectional Study
Ganesh, Ravindra , Ghosh, Aditya , Nyman, M. , Croghan, Ivana T. , Grach, Stephanie L. , Anstine, Christopher V. , Salonen, Bradley R. , Ghosh, Aditya K, Nyman, Mark A, Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L , Ghosh, Aditya K

Mayo Clinic

Journal of Primary Care & Community Health | July 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211030413 | PMID 34231395 Get It

Objective Persistent post-COVID symptoms are estimated to occur in up to 10% of patients who have had COVID-19. These lingering symptoms may persist for weeks to months after resolution of the acute illness. This study aimed to add insight into our understanding of certain post-acute conditions and clinical findings. The primary purpose was to determine the persistent post COVID impairments prevalence and characteristics by collecting post COVID illness data utilizing Patient-Reported Outcomes Measurement Information System (PROMIS ® ). The resulting measures were used to assess surveyed patients physical, mental, and social health status. Methods A cross-sectional study and 6-months Mayo Clinic COVID recovered registry data were used to evaluate continuing symptoms severity among the 817 positive tested patients surveyed between March and September 2020. The resulting PROMIS ® data set was used to analyze patients post 30 days health status. The e-mailed questionnaires focused on fatigue, sleep, ability to participate in social roles, physical function, and pain. Results The large sample size (n = 817) represented post hospitalized and other managed outpatients. Persistent post COVID impairments prevalence and characteristics were determined to be demographically young (44 years), white (87%), and female (61%). Dysfunction as measured by the PROMIS ® scales in patients recovered from acute COVID-19 was reported as significant in the following domains: ability to participate in social roles (43.2%), pain (17.8%), and fatigue (16.2%). Conclusion Patient response on the PROMIS ® scales was similar to that seen in multiple other studies which used patient reported symptoms. As a result of this experience, we recommend utilizing standardized scales such as the PROMIS ® to obtain comparable data across the patients’ clinical course and define the disease trajectory. This would further allow for effective comparison of data across studies to better define the disease process, risk factors, and assess the impact of future treatments.
Abstract 17150: LDL-C Response to Portfolio Foods Containing High Levels of Phytosterols, Whole Food Fiber, and Alpha-Linoleic Acid in Statin Reluctant Patients: Impact of CYP7A1-rs3808607 and APOE Isoforms
Kopecky, Stephen L. , Klodas, Elizabeth , Alias, Soumya, Bauman, Jessica R. , Jew, Stephanie, Bauman, Jessica, Jones, Peter J.H.

Mayo Clinic

Circulation | July 2, 2021 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.17150 Get It

Introduction: Up to 20% of outpatients receiving HMG-CoA reductase inhibitors (statins) experience treatment reluctance on the basis of side effects, leaving a large population at increased risk of CVD. We hypothesized that a practical food-based approach can be utilized to lower LDL-C in statin reluctant patients and that the lipid response can be predicted based upon CYP7A1-rs3808607 (CYP7A1) and APOE genetic isoforms. Methods: This was a multicenter, randomized, double-blind, free-living cross-over study composed of 2 phases of 4 wk each, separated by a 4 wk washout. Participants (n=54) received an assortment of individually packaged, shelf stable snacks along with printed instructions to ingest 2 servings of the foods per day as a substitute for similar items they were eating already. No other dietary or behavior adjustments were requested. Treatment products supplied at least 1800 mg alpha-linoleic acid (ALA), 5 g of fiber and 1g of phytosterols per serving. Control products were calorie-matched like items drawn from the general grocery marketplace. Lipid parameters were measured and averaged over 2 d at baseline and at 4 wk of each phase. Ingestion of study foods was confirmed by C18:3n3 serum level assessment. Single nucleotide polymorphisms and APOE isoform were assessed by Taqman genotyping assay. Results: As compared to control, LDL-C decreased 8.8% in the treatment arm (p<0.0001, range -37.6% to +20.5%) and total cholesterol fell 5.1% (p<0.004). No significant change was seen in HDL-C, TG or fasting glucose levels. LDL-C was reduced by diet in CYP7A1 T/T homozygotes (-0.3924+0.1271mmol/l, p = 0.0033) and APOE4 carriers ( -0.3808+0.098 mmol/l, p = 0.0003). Conclusions: Significant LDL-C reductions can be affected through a simple food intervention supplying high levels of phytosterols, fiber and ALA. CYP7A1 and APOE isoforms influence the variability in LDL-C response and can help identify individual patients especially appropriate for a food-based LDL-C lowering approach. Given the large number of patients unable/unwilling to take statins, our findings have significant impact for management of this challenging population.
Interstitial amyloidosis in sporadic inclusion body myositis
Alamr, Mazen , Milone, Margherita , Naddaf, Elie , Ytterberg, Steven R. , Steel, Stephanie J., Liewluck, Teerin , Liewluck, T , Naddaf, Elie , Jones, Lyell K.

Mayo Clinic

Muscle & Nerve | July 2, 2021 | Volume: 64 | Issue: 5 | Pages: 590-594

10.1002/mus.27362 | PMID 34196979 Get It

Abstract Introduction/Aims Intracellular congophilic inclusions within muscle fibers, although nonspecific, are one of the pathological hallmarks of sporadic inclusion body myositis (sIBM). Extracellular amyloid deposits in muscle, on the other hand, are the canonical findings of amyloid myopathies, which occur with or without systemic amyloidosis. Methods We reviewed the muscle biopsy database (1998–2020) to identify sIBM patients with extracellular amyloid deposits. Clinical and laboratory data were reviewed. Results We identified five sIBM patients (three clinicopathologically defined and two clinically defined) with extracellular amyloid deposits in muscle. Mean age at diagnosis was 74.8 y (range, 68–84 y). All patients had a typical sIBM pattern of weakness without associated sensory or autonomic symptoms. None had electrophysiological evidence of peripheral neuropathy. Only one patient had a monoclonal gammopathy (immunoglobulin M‐lambda, IgM‐λ) with normal bone marrow biopsy. This patient with monoclonal gammopathy and three other patients underwent abdominal fat pad aspirate and were negative for amyloid. Cardiac evaluation was unrevealing in the four patients tested. Three patients without monoclonal gammopathy had normal transthyretin gene sequencing and inconclusive mass spectrometry‐based analysis. The patient with monoclonal gammopathy died of pneumosepsis 5 y after diagnosis and autopsy revealed multi‐organ transthyretin amyloidosis. Discussion Detection of extracellular amyloid deposition in muscle should trigger an aggressive search for systemic amyloidosis independently from other associated myopathological abnormalities. Amyloid subtyping is crucial for early therapy and mortality prevention. An isolated monoclonal gammopathy should not halt a search for non‐hematological causes of systemic amyloidosis.
Abstract 2528: Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415
Pugh, Stephanie L. , Zhang, Qi , Shah, Amit B. , Dayes, Ian S. , D’Souza, David , Michalski, Jeff M. , Longo, J.M., Pisansky, Thomas M. , Maier, Jordan, Faria, Sergio , Desai, Anand , Dayes, Ian S , Bai, Jinbing , Eldridge, Ronald C. , Yeager, Katherine A. , Lee, W. Robert , Efstathiou, Jason A. , Seaward, Samantha A , Sandler, Howard M. , Cooley, Mary E. , Bruner, Deborah Watkins

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 2528-2528

10.1158/1538-7445.am2021-2528 Get It

Abstract Background: Prostate cancer is the most common cancer among men. Monitoring of patient-reported outcomes (PROs) can enhance provider-patient communication, promote better decision-making, and improve survival. Geospatial factors, namely rurality and neighborhood socioeconomic deprivation, could influence the experience across cancer treatment, thus impacting PROs and survival. This study examined associations of rurality, neighborhood socioeconomic deprivation (Area Deprivation Index [ADI]) with cancer treatment-related PROs and survival in men with prostate cancer. Methods: Data from men with prostate cancer in the trial NRG Oncology/RTOG 0415 were analyzed. In this trial, 1092 men were randomized to receive conventional radiotherapy (RT) or hypofractionated RT. Patients had Gleason scores of 2-6 and prostate-specific antigen of &lt;10 ng/mL. Rurality was categorized as urban vs rural using Rural-Urban Continuum Codes via patient zip codes. Neighborhood socioeconomic deprivation was assessed by the ADI calculated via the American Community Survey by patient zip codes. The Expanded Prostate Cancer Index Composite (EPIC) measures cancer-specific quality of life (QOL); Hopkins Symptom Checklist measures anxiety and depression; EuroQoL-5 Dimension (EQ-5D) VAS and Index scores assess general health. All PROs were measured at baseline before and 6, 12, 24 and 60 months after RT. Overall survival (OS) and disease-free survival (DFS) were assessed using Cox proportional hazards models. Mixed effects models and generalized estimating equations were used to analyze PROs. Results: We analyzed 751 patients with complete data. Patients from the ADI 25% most deprived neighborhoods (vs. the other 75% of neighborhoods) were more likely to be non-white, unmarried and from rural areas. At baseline, patients from the most deprived areas had worse EPIC bowel score (P=0.011), worse sexual score (P=0.042) and worse hormonal score (P=0.015); patients from the most deprived areas had worse self-care (P=0.04) and more pain (P=0.047). Patients from rural areas had worse EPIC urinary score (P=0.03) and sexual score (P=0.003). Longitudinal analyses showed that ADI 25% most deprived areas (β=4.05, P=0.001) and rural areas (β=-5.70, P=0.003) were associated with worse EQ-5D VAS score. Compared to the 75% less deprived neighborhoods and urban, the ADI 25% most deprived neighborhoods and rural areas respectively had 47% (HR=1.466, P=0.033) and 93% (HR=1.925, P=0.026) relative increase in risk of recurrence or death (DFS). No differences were seen in OS. Conclusions: Patients with prostate cancer from the most deprived neighborhoods and rural areas had low QOL at baseline, poor general health and DFS. Interventions should target populations from socioeconomic deprived neighborhoods and rural areas to improve patient access to supportive care services and DFS. Citation Format: Jinbing Bai, Stephanie L. Pugh, Ronald Eldridge, Katherine Yeager, Qi Zhang, W Robert Lee, Amit B. Shah, Ian S. Dayes, David P. D'Souza, Jeff M. Michalski, Jason A. Efstathiou, John M. Longo, Thomas M. Pisansky, Jordan M. Maier, Sergio L. Faria, Anand B. Desai, Samantha A. Seaward, Howard M. Sandler, Mary E. Cooley, Deborah W. Bruner. Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2528.
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
Collaborative, REACCT, Zaborowski, Alexandra , Abdile, Ahmed, Adamina, Michel , Aigner, Felix , d’Allens, Laura, Allmer, Caterina, Álvarez, Andrea, Anula, Rocío, Atallah, S. , Bach, Simon P. , Barussaud, Marie, Baušys, Augustinas , Bebington, Brendan , Beggs, Andrew D. , Bellolio, Felipe, Bennett, Melissa-Rose , Berdinskikh, Anton, Bevan, Vicki, Bislenghi, Gabriele , Bludau, Marc , Boutall, Adam , Brouwer, Nelleke P.M. , Bruns, Christiane J. , Burger, Jacobus W. A. , Бурлов, Никита , Campanelli, Michela , Capdepont, Maylis, Carvello, Michele , Chew, Hwee-Hoon, Christoforidis, Dimitri, Clark, David A. , Climent, Marta, Cologne, Kyle G. , Contreras, Tomás, Croner, Roland S. , Daniels, I. R. , Delrio, Paolo , Deutsch, Michael , D’Hoore, André , Drozdov, E. S. , Duek, Daniel, Dunlop, Malcolm G. , Edmundson, Aleksandra , Efetov, Sergey , El‐Hussuna, Alaa , Elliot, Brodie, Espín, Eloy , Faes, Seraina , Faiz, Omar , Frasson, Matteo , Figueiredo, Nuno , Forgan, Tim , Frizelle, Frank , Gadaev, Shamil, Gellona, José, Glyn, Tamara , Gong, Jianping, Barisic, Goran, Greenwood, Emma, Guren, Marianne G. , Guillon, Stephanie, Gutlic, Ida , Hanly, Ann, Hasegawa, Hirotoshi , Iversen, Lene Hjerrild , Hill, James , Hoch, Jiří, Hoffmeister, Michael , Hompes, Roel , Hurtado‐Pardo, Luis , Iaquinandi, Fabiano , Imbrasaitė, Ugnė , Jafari, Mehrenah Dorna, Kanemitsu, Yukihide , Karimuddin, Ahmer , Keller, Deborah S. , Kelly, Justin, Kennelly, Rory , Khrykov, Gleb , Kocián, Petr , Koh, Cherry , Kok, N. F. M., Knight, Katrina , Knol, Joep, Kontovounisios, Christos , Kørner, Hartwig , Kronberger, Irmgard, Kroon, Hidde M. , Kural, Said , Lakkis, Zaher , Lankov, Timur , Larson, Dave, Lázár, György , Lee, Kai-Yin , Lepistö, Anna , Loi, Lynette , Lynch, Craig, Maillou‐Martinaud, Helene, Maroli, Annalisa , Martling, Anna , Matzel, Klaus E. , Mayol, Julio , McDermott, Frank , Meurette, G. , Mitteregger, Martin , Моисеенко, А С, Monson, John R.T. , Moritani, Konosuke , Munini, Martino , Nahas, Caio Sérgio Rizkallah , Negoi, Ionuţ , Novikova, A , Ocares, Misael, Olkina, Alexandra, Oñate‐Ocaña, Luis F. , Otero, Jaime, Özen, Cihan , Pace, Ugo , Julião, Guilherme Pagin São , Panaiotti, Lidiia , Panís, Yves , Papamichael, Demetris , Uriburu, Juan C Patrón , Pera, Miguél , Perez, Rodrigo Oliva , Pfeffer, F. , Phang, P. Terry , Poškus, Tomas , Pringle, Heather , Proud, David , Raguz, Ivana , Rama, N. , Rasheed, Shahnawaz, Raval, Manoj J. , Reißfelder, Christoph , Meneses, Juan Carlos Reyes , Ris, Frédéric , Riss, Stefan , Rodríguez‐Zentner, Homero , Saklani, Avanish , Salido, Andrea Jiménez, Sammour, Tarik , Saraste, Deborah , Schneider, Martin , Seishima, Ryo , Sekulic, Aleksander , Seppälä, Toni T. , Sheahan, Kieran , Shine, Rebecca , Shlomina, Alexandra , Sica, Guiseppe S., Singnomklao, T, Siragusa, Leandro , Spinelli, Antonino , Staiger, Roxane D. , Stamos, Michael J. , Sunderland, Michael, Tan, Ker‐Kan , Tanis, Pieter J. , Tekkis, Paris, Teklay, Biniam, Tengku, Sabrina , Jiménez‐Toscano, Marta , Turina, Matthias , Ulrich, Alexis , Vailati, Bruna Borba , Harten, Meike van, Warrier, Satish K. , Wexner, Steve, Wilt, Hans De, Xynos, Evangelos , You, Nancy, Zakharenko, Alexander, Zeballos, Justino, Winter, D. C. , Wexner, Steven D. , Hoffmeister, Michael , Seppälä, Toni T , Spinelli, Antonino , Wexner, Steven D , Ris, Frederic , Collaborative, REACCT, Andric, Mihailo , Bala, Miklosh , Biondo, Sebastiano , Brown, Carl James , Buchanan, Daniel D. , Buchwald, Pamela , Dapri, Giovanni , Davies, Justin , Denost, Quentin , Dias, André Roncon , Dziki, Adam Janusz , Emile, Sameh Hany , Evans, Martyn D. , Fleming, Fergal J. , Foppa, Caterina , Fowler, G , Gong, Jianping, Greenwood, Emma, Hahnloser, Dieter , Hampel, Heather , Hill, Andrew Graham , Islam, Rumana, Jafari, Mehrenah D, Карачун, А. М. , Krivokapić, Zoran , Kryžauskas, Marius , Kusters, Miranda , Lee, Suk-Hwan , Lefèvre, Jérémie H. , Lieu, Christopher H. , Martin, Sean, Millán, Mónica , Morărașu, Ștefan , Möslein, Gabriela , Nahas, Sérgio Carlos , Okabayashi, Koji , Олькина, Александра Юрьевна , Park, Jason , Patel, Swati , Petrov, Alexei, Rega, Daniela , Roxburgh, Campbell S.D. , Smart, Neil James , Solis, Alejandro, Steele, Scott R. , Владимирович, Царьков Петр , Verhoef, Cornelis , Weinberg, Benjamin A. , Wells, Cameron I. , Wolthuis, Albert M.

Mayo Clinic

JAMA Surgery | June 30, 2021 | Volume: 156 | Issue: 9 | Pages: 865

10.1001/jamasurg.2021.2380 | PMID 34190968 Get It

Association of vitamin D deficiency with COVID‐19 infection severity: Systematic review and meta‐analysis
Joshi, Avni Y. , Leopold, Kaitlin , Christensen, Stephanie , Nayfeh, Tarek , Mohammed, Khaled , Creo, Ana L. , Tebben, Peter J. , Kumar, Seema , Joshi, Avni, Jackson, Sarah, Creo, Ana , Tebben, Peter, Kumar, Seema , Nayfeh, Tarek , Tebben, Peter , Wang, Zhen , Jackson, Sarah

Mayo Clinic

Clinical Endocrinology | June 23, 2021 | Volume: 96 | Issue: 3 | Pages: 281-287

10.1111/cen.14540 | PMID 34160843 Get It

AbstractBackgroundWe sought to evaluate the association between vitamin D deficiency and the severity of coronavirus disease 2019 (COVID‐19) infection.MethodsMultiple databases from 1 January 2019 to 3 December 2020 were searched for observational studies evaluating the association between vitamin D deficiency and severity of COVID‐19 infection. Independent reviewers selected studies and extracted data for the review. The main outcomes of interest were mortality, hospital admission, length of hospital stay and intensive care unit admission.ResultsSeventeen observational studies with 2756 patients were included in the analyses. Vitamin D deficiency was associated with significantly higher mortality (odds ratio [OR]: 2.47, 95% confidence interval [CI]: 1.50–4.05; 12 studies; hazard ratio [HR]: 4.11, 95% CI: 2.40–7.04; 3 studies), higher rates of hospital admissions (OR: 2.18, 95% CI: 1.48–3.21; 3 studies) and longer hospital stays (0.52 days; 95% CI: 0.25–0.80; 2 studies) as compared to nonvitamin D deficient status. Subgroup analyses based on different cut‐offs for defining vitamin D deficiency, study geographic locations and latitude also showed similar trends.ConclusionsVitamin D deficiency is associated with greater severity of COVID‐19 infection. Further studies are warranted to determine if vitamin D supplementation can decrease the severity of COVID‐19.
Abstract 152: Genome-wide Association Study of Early-Onset Ischemic Stroke Identifies Novel Locus on Chromosome 12 Near BCL7A/MLXIP
Jaworek, Thomas , Kittner, Steven J. , Leeuw, F.E. de, Malik, Rainer, Fernandez, Israel, Słowik, Agnieszka , Boncoraglio, Giorgio Boncoraglio, Jiménez-Conde, Jordi , Schmidt, Reinhold, Sharma, Pankah, Rothwell, Peter M. , Sudlow, Catherine, Markus, Hugh S. , Salaheen, Danish, Worrall, Bradford B. , Woo, Dan, Irvin, Ryan, Rexrode, Kathyn, Smoller, Sylvia, Mueller, Martina, Jern, Christina , Dichgans, Martin , Malik, Rainer , Boncoraglio, Giorgio B. , Lindgren, Arne G. , Lemmens, Robin , Melander, Olle , Levi, Christopher , Sudlow, Catherine, Debette, Stéphanie , Howson, Joanna M. M. , Paré, Guillaume , Zand, Ramin , Worrall, Bradford B. , Meschia, James F. , Rundek, Tatjana , Lee, Jin‐Moo , Rosand, Jonathan M. , Salomaa, Veikko

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.152 Get It

Introduction: Genetic studies of early-onset disease have been an effective strategy to identify novel pathways and drug targets relevant to later-onset disease. Few studies have investigated the role of common genetic variation in the etiology of early-onset ischemic stroke (IS). Methods: We performed a GWAS meta-analysis of 38 studies from 10 countries, comprised of 5,847 IS cases of European ancestry under age 60 and 32,533 controls. Results: We identified two genome-wide significant (p< 5 x 10 -8 ) loci (see Figure). The ABO locus has previously been associated with venous thrombosis and ischemic stroke in predominantly older adults, but the effect size of our top SNP (OR 1.18; p = 9.1 x 10 -12 ) is larger than the effect size for this same SNP in MEGASTROKE (OR: 1.05; p = 6.5 x 10 -5 ). The lead SNP at the BCL7A/MLXIP locus is a novel GWAS finding for stroke (OR 1.14, 95% CI 1.08-1.19; p = 1.7 x 10 -8 ) and is noteworthy because of prior reports linking SNPs in these genes to BMI and blood pressure. Conclusions: We identified a novel locus that is near variants associated with BMI and blood pressure. Further studies are needed to confirm this locus, examine subtype specificity, and determine its function. The larger effect size observed at the ABO in this early-onset IS sample compared to older-onset IS samples is consistent with a larger role for prothrombotic mechanisms in early-onset IS.
Upregulation of CD56 expression and T‐cell receptor (TCR)‐independent activation of T cells with aging
Lemster, Bonnie , Montag, David T. , Paat, John, Studenski, Stephanie A. , Vallejo, Abbe N. , Michel, Joshua J. , Newman, Anne B.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.662.11 Get It

Degeneration of the thymus and severe contraction of the T‐cell repertoire with aging suggest that immune homeostasis in old age could be mediated by distinct effectors. Therefore we examined receptors expressed on T cells as they undergo senescence in vitro , and those displayed by circulating T cells during normal chronologic aging. Monitoring of T cells driven to senescence showed de novo induction of CD56, the prototypic receptor of NK cells. Analysis of fresh T cells in blood showed an age‐dependent induction of CD56. These unusual T cells expressed high levels of Bcl2, p16, and p53, and had limited, or completely lost, ability to undergo cell division; properties consistent with senescence. CD56 cross‐linking without TCR ligation on CD56 + T cells resulted in extensive protein phosphorylation, NFκB activation, and Bax down‐regulation. CD56 cross‐linking was also sufficient to drive production of various humoral factors. These data indicate that the immunologic environment in old age is functionally distinct, rather than a dysfunctional version of that seen at a young age. In view of the reported inefficiencies of TCR‐driven immunity with aging, elicitation of TCR‐independent immune cascades by CD56 + T cells provide new avenues for the development of alternative strategies to enhance protective immunity in the elderly. [Supported by NIH grants R01‐AG022379, R01‐AG023629, P20‐CA103730, and T35‐AG026778].
Abstract 181: What’s in the Black Box?: Describing Current Practice, Challenges, and Barriers of Cardiology and Palliative Care Collaboration
Mancarella, G, Wordingham, Sara E., Goodlin, Sara, Blume, Elizabeth D. , Cooper, Stephanie , Josephson, Richard , Cestoni, Abby, Hauptman, Paul J., Wells, Rachel D. , Dionne-Odom, James Nicholas , McIlvennan, Colleen Kelley , Goodlin, Sarah J. , Alexander, Karen P. , Maurer, Matthew, Hauptman, Paul J. , Kirkpatrick, James N , Bakitas, Marie , Swetz, Keith M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.181 Get It

Background: Guidelines recommend involvement of palliative care (PC) for patients with cardiovascular (CV) disease and their families. Little is known about the current integration of PC and CV services. Research Objectives: Our national survey aimed to describe current practices and to identify benefits, challenges, and barriers with collaboration. Methods: Qualitative content analysis of open-response questions in an investigator-developed electronic survey study of CV and PC providers (MDs, NPs, PAs, and other allied health) using email listservs, social media, and crowdsourcing. Frequencies were tabulated using SAS statistical software. Results: Of 134 respondents, most were physicians (n=56, 57%) or advanced practice RNs or PAs (n=37, 28%), from 52 U.S. institutions, representing 33 states. The most common care for which PC was integrated were mechanical circulatory support, advanced heart failure, and heart transplantation; the least common care for which PC was integrated were TAVR, ECMO, and pulmonary hypertension. Integrated practice (n=80, 61%), PC identification of goals of care (n=20, 15%) and PC aid in patient/family communication (n=15, 11%) were the most commonly identified as positives in current practice. PC provider workforce (n=22, 16%), underutilization of PC referrals (n=20, 15%), late disease PC referral (n=19, 14%), and fundamental knowledge deficit of specialty scope (n=18, 14%) were most frequently identified as challenges. Other barriers specifically noted were underdeveloped health infrastructure and limited allocated resources (n=23,17%) and mis-/negative perception of services (n=15, 11%). Conclusion: PC and CV collaboration occurs for a high proportion of CV patients and is viewed as overwhelming positive, despite the challenges of limited PC specialists availability, underdeveloped healthcare infrastructure, limited understanding of specialty practice, and late referrals. Priorities includes increasing PC provider availability, expanding knowledge of PC services, educating providers on models of collaboration, and improving institutional support.